Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.

University of Maryland School of Medicine, Department of Neurology, MD, USA.
Journal of Neuroimmunology (Impact Factor: 3.03). 04/2007; 185(1-2):168-74. DOI: 10.1016/j.jneuroim.2007.01.011
Source: PubMed

ABSTRACT We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-gamma) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-beta-1a 30 microg intramuscularly (IM) (n=8) or three-times-weekly (tiw) IFN-beta-1a 44 microg subcutaneously (SC) (n=7). Overall, IFN-beta treatment increased cellular IL-10 (p<0.01) levels and the ratios of cellular IL-10/IL-12p40 (p<0.01) and IL-10/IL-12p70 (p<0.02) while cellular IFN-gamma levels were reduced (p<0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p<0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p=0.031) and a decrease in cellular IL-12p70 (p<0.02). A decrease in cellular IFN-gamma was observed in responders (p=0.013). This is the first study that compares cytokine changes between the two IFN-beta regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interferon-beta (IFN-beta) is an immunomodulatory drug of choice to control relapsing-remitting multiple sclerosis (RR-MS), although its function is still unclear. A reduced suppressive function of CD4(+)CD25(+) regulatory T cells (T(reg)) has been shown in RR-MS patients. In this study, to understand the effect of IFN-ss on CD4(+)CD25(+) regulatory T cells, we analyzed the frequency and function of these cells and Foxp3 gene expression before and after treatment. We evaluated the frequency and function of CD4(+)CD25(+)Foxp3(+) regulatory T cells by flow cytometry and co-culture inhibition test respectively and gene expression of Foxp3 by real-time PCR in a longitudinal follow-up study in 18 relapsing-remitting MS patients. Our data revealed that IFN-beta significantly improved frequency and suppressive function of T(reg) cells (P<0.05) without any significant effect on gene expression of Foxp3 after 6 months. The results of the present study indicate that IFN-beta therapy in some of patients with RR-MS may restore function of regulatory T cells and control the unchecked immune cascade activity. Larger longitudinal studies on more MS patients are required to confirm our findings.
    Journal of neuroimmunology 11/2009; 218(1-2):120-4. · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is characterized by episodes of inflammatory damage to myelin and oligodendrocytes in the central nervous system mediated by T, B, and Natural killer lymphocytes of various types, antibody and complement, dendritic cells, macrophages, microglia, and secreted cytokines and chemokines. These relapses cause significant neurologic dysfunction, which is only partially reversible, and eventual secondary progressive neurologic decline frequently occurs. Interferon-beta (IFNβ) has been a mainstay of MS treatment for more than 20 years after being proven to reduce relapse frequency and development of new lesions on magnetic resonance imaging. However, patient response is highly variable and the exact mechanisms of action are not fully understood. Breakthrough relapses and secondary progressive neurologic decline remain significant concerns in long-term MS treatment. Biomarkers may help elucidate the beneficial effects of IFNβ in MS and possibly guide therapeutic decision making given the variety of different therapies now available with varying mechanisms of action and risks. Various serum and cerebrospinal fluid candidate biomarkers have been described, but none have yet been proven to carry sufficient predictive reliability for routine clinical use.
    08/2014; 34(8):600-4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Beneficial effects by both interferon-beta and statin treatment in patients with multiple sclerosis (MS) may be linked to interference with the Th1/Th2 cytokine balance. We determined patterns of Th1/Th2 cytokines (interleukin (IL)-1beta, IL-2, IL-6, IL-12p70, tumor-necrosis factor (TNF)-alpha and interferon-gamma, and IL-4, IL-5 and IL-10, respectively) in the serum of patients with relapsing-remitting MS treated with 250microg interferon-beta 1b or with interferon-beta plus 40mg atorvastatin. In treatment naïve patients with MS, a trend for lower TNF-alpha serum levels compared to controls was detected (P=0.08). Interferon-beta treatment increased TNF-alpha levels, while a trend for lowering of IL-5 serum levels was found (P=0.07). Addition of atorvastatin raised IL-12p70 serum levels (P<0.05). Mean levels of two Th2 cytokines (IL-4, IL-10) showed a non-significant increase after addition of atorvastatin. We conclude that interferon-beta and atorvastatin exert divergent action on Th1/Th2 serum cytokines levels in MS. Supplemental atorvastatin might promote a Th1-type response by raising IL-12p70. Further studies are required to support a Th2 cytokine shift by atorvastatin in patients with MS.
    Neurochemistry International 07/2008; 53(1-2):17-21. · 2.66 Impact Factor


Available from